|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 13, 2015 ) The report covers present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.
CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.
The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.
Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.
The analysts forecast global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.
Purchase a Report Copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=402226 .
Covered in this Report
The report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Americas
APAC
EMEA
Key vendors
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck & Co
Tesaro
Inquire before Buying at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=402226 .
Other prominent vendors
Acacia Pharma
Aphios
Barr Laboratories
Baxter Healthcare
Eisai
Especificos Stendhal
F.Hoffmann La Roche
Mundipharma
Mylan Pharmaceuticals
OPKO Health
Orchid Healthcare
Otsuka Pharmaceutical
ProStrakan
Sandoz (Novartis)
Solvay Pharmaceuticals
Specialised Therapeutics Australia
Sun Pharma
Taiho Pharmaceutical
Teva Pharmaceuticals
Market driver
Increase in incidence and prevalence of cancer
Market challenge
Complex physiology of CINV
Market trend
Increased use of combination therapies
Inquire for Discount at http://www.rnrmarketresearch.com/contacts/discount?rname=402226 .
Key Questions Answered in this Report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
RnR Market Research
Ritesh Tiwari
1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
